As of November 10, 2026, NovoCure Ltd is a publicly traded company (Nasdaq: NVCR); its largest reported holder is Soleus Capital Master Fund, L.P., with 8.1% on Schedule 13G/A of November 9, 2026, then Vanguard (5.57%). The largest insider holding is Frank X. Leonard, the chief executive, with 461,425 shares (0.39% of shares outstanding), per Form 4 of July 1, 2026 (Schedule 13G/A, November 9, 2026).
Is this your company?
About to sign with, pay or invest in NovoCure Ltd? See the free Snapshot first.
Free to see. No signup.
Is NovoCure Ltd a real, registered company?
- NovoCure Ltd files with the SEC under CIK 1645113 (its SEC filings).
- Its shares are listed under the ticker NVCR on Nasdaq (SEC company record).
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NovoCure Ltd in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Timothy Scannell, Director (Form 8-K filed 2026-09-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Soleus Capital Master Fund, L.P. (filed 2026-11-09).
Who are NovoCure Ltd's owners and officers?
NovoCure Ltd: industry Surgical & Medical Instruments & Apparatus (Schedule 13G/A, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-09 | Soleus Capital Master Fund, L.P. | 8.1% |
| Schedule 13G/A, 2026-05-08 | Soleus Capital Master Fund, L.P. | 9.1% |
| Schedule 13G, 2026-04-28 | Vanguard Portfolio Management | 5.57% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | Soleus Capital Master Fund, L.P. | 7.6% |
| Schedule 13G/A, 2025-11-13 | Capital World Investors | 1.8% |
| Schedule 13G/A, 2025-11-07 | Soleus Capital Master Fund, L.P. | 8.6% |
| Schedule 13G, 2025-08-13 | Capital World Investors | 5.7% |
| Schedule 13G/A, 2025-08-05 | Soleus Capital Master Fund, L.P. | 6.2% |
| Schedule 13G/A, 2025-07-07 | Capital International Investors | 0% |
Questions about who owns NovoCure Ltd
Who owns NovoCure Ltd?
On this page, 2 holders' latest ownership filings report 5% or more of NovoCure Ltd: Soleus Capital Master Fund, L.P. (8.1%, Schedule 13G/A, filed 2026-11-09) and Vanguard Portfolio Management (5.57%, Schedule 13G, filed 2026-04-28).
Who are the largest shareholders of NovoCure Ltd?
By the share each holder's latest filing reports, the largest holders of NovoCure Ltd on this page are Soleus Capital Master Fund, L.P. (8.1%) and Vanguard Portfolio Management (5.57%).
When did Soleus Capital Master Fund, L.P. buy into NovoCure Ltd?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13G/A, filed 2025-08-05, reporting 6.2%; its latest, Schedule 13G/A filed 2026-11-09, reports 8.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on NovoCure Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NovoCure Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NovoCure Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-09 | Timothy Scannell | Director | departed | 2026-09-02 |
Which insiders own NovoCure Ltd shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive: 461,425 shares (0.39% of shares outstanding) (Form 4, 2026-07-01).
- , the chief executive: 422,570 shares (0.36% of shares outstanding) (Form 4, 2026-03-05).
- , a director: 416,742 shares (0.36% of shares outstanding) (Form 4, 2026-07-01).
- , the chairman and a director: 328,397 shares (0.28% of shares outstanding) (Form 4, 2026-03-05).
- , the chf medical and innovation ofr: 267,190 shares (0.23% of shares outstanding) (Form 4, 2026-03-05).
Shares outstanding: 116,915,959 as of 2026-10-23, from the company's latest SEC cover page.
How much has NovoCure Ltd raised?
No fundraising or offering filing from NovoCure Ltd is on file with us.
Keep reading
More on NovoCure Ltd and the records around it.
NovoCure Ltd elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/novocure